Pharmacokinetics of telithromycin: Application to dosing in the treatment of community-acquired respiratory tract infections

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1641-1650

  Ciervo, Carman A ^a   Shi, Jun ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b SANOFI   (France)

Author keywords

Bronchitis, acute; Community acquired infection; CYP3A; Drug interactions; Ketolides; Pharmacokinetics; Pneumonia; Sinusitis; Telithromycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ATORVASTATIN; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; KETOLIDE; LINCOSAMIDE; MACROLIDE; METOPROLOL; MEVINOLIN; MIDAZOLAM; PENICILLIN G; PHENYTOIN; PIMOZIDE; RIFAMPICIN; SIMVASTATIN; STREPTOGRAMIN; TELITHROMYCIN; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ACUTE DISEASE; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL STRAIN; BIOLOGICAL MONITORING; BRONCHOPNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TOLERABILITY; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GERMANY; HAEMOPHILUS INFLUENZAE; HEPATITIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER METABOLISM; LUNG ALVEOLUS EPITHELIUM; MEDLINE; MORAXELLA CATARRHALIS; NAUSEA; PHARMACODYNAMICS; PROTHROMBIN TIME; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINUSITIS; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; TISSUE DISTRIBUTION; UNITED STATES; VISUAL IMPAIRMENT; VOLUNTEER;

AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BRONCHITIS; COMMUNITY-ACQUIRED INFECTIONS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; KETOLIDES; KIDNEY DISEASES; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; SINUSITIS;

EID: 27144545815     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65466     Document Type: Review

References (54)

1. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130:1-45
2. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82
3. Saint S, Flaherty KR, Abrahamse P, et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther 2001;23: 499-512
4. Bonnefoy A, Girard AM, Agouridas C, et al. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997;40:85-90
5. Nord CE, Farrell DJ, Leclercq R. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microb Drug Resist 2004;10:255-63
6. Lorenz J. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections. Int J Clin Pract 2003;57:519-29
7. Hagberg L, Carbon C, van Rensburg DJ, et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003;97:625-33
8. Aventis. Ketek® (telithromycin) Tablets. 2005. Available from www.fda.gov/cder/foi/label/2005/21144s001,0031b1.pdf [Accessed 12 April 2005]
9. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
10. Roos K, Baz M, Leroy B, et al. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect 2005;50:210-20
11. Fogarty C, Zervos M, Tellier G, et al. Telithromycin for the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract 2005;59:296-303
12. Bryskier A. Ketolides - telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661-9
13. Sultan E, Namour F, Mauriac C, et al. HMR 3647, a new ketolide antimicrobial, is metabolized and excreted mainly in feces in man. J Antimicrob Chemother 1999;44(Suppl A):54
14. Perret C, Lenfant B, Weinling E, et al. Pharmacokinetics and absolute oral bioavailability of an 800mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002;48:217-23
15. Bhargava V, Lenfant B, Perret C, et al. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 2002;34:823-6
16. Aventis. Ketek® (telithromycin) briefing document for the FDA anti-infective drug products advisory committee meeting, January 2003. Available from www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf [Accessed 12 April 2005]
17. Edlund C, Alvan G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000;46:741-9
18. Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001;45:170-5
19. Cantalloube C, Bhargava V, Sultan E, et al. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents 2003;22:112-21
20. Shi J, Montay G, Hardy P, et al. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 2005;25:42-51
21. Shi J, Montay G, Chapel S, et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol 2004;44:234-44
22. Khair OA, Andrews JM, Honeybourne D, et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001;47:837-40
23. Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001;45:3104-8
24. Muller-Serieys C, Andrews J, Vacheron F, et al. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53:149-57
25. Low DE, Felmingham D, Brown SD, et al. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infection 2004;29:115-25
26. Nicolau DP. Clinical use of antimicrobial pharmacodynamic profiles to optimize treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. Expert Opin Pharmacother 2004;5:229-35
27. Vesga O, Bonnat C, Craig WA. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [Abstract F255]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto, Canada
28. Pluim J. Population pharmacokinetics support the convenient once-daily 800mg dosage of telithromycin in patients with upper and lower RTIs, including special populations. Clin Microbiol Infect 2001;7(Suppl 1):266
29. Sultan E, Lenfant B, Wable C, et al. Pharmacokinetic profile of the new ketolide HMR 3647 800mg once daily in elderly volunteers. J Antimicrob Chemother 1999;44(Suppl A):54
30. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19(Suppl A):29-37
31. Rodvold K. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385-98
32. Shi J, Montay G, Leroy B, et al. Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic [Abstract Al 833]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA
33. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005;43:123-33
34. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44:915-34
35. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51
36. Labbe G, Flor M, Lenfant B. Cytochrome P-450 activity is not inhibited in vitro by telithromycin (HMR 3647), a new ketolide [Abstract 09.23]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26-28, 2000, Seville, Spain
37. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides. Focus on respiratory tract infections. Drugs 2001;61:443-98
38. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(Suppl 1):III50-7
39. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26-31
40. Combalbert J, Fahre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207
41. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8
42. Wallace Jr RJ, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171: 747-50
43. Lippert C, Leese PT, Sultan E. Telithromycin (HMR 3647) does not interact with CYP2D6 substrate paroxetine. Clin Microbiol Infect 2001;7(Suppl 1):267 [Abstract P1268]
44. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21(Suppl 10):253s-72s
45. Bhargava V, Leroy B, Shi J, et al. Effect of telithromycin on pharmacokinetics of theophylline in healthy volunteers [Abstract A-1832]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA
46. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31
47. Abbott Laboratories. Biaxin® (clarithromycin) prescribing information; 2003. Available at www.biaxin.com/pdf/biapi [Accessed 30 November 2004]
48. Montay G, Shi J, Leroy B, et al. Effects of telithromycin on the pharmacokinetics of digoxin in healthy men [Abstract A-1834]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA
49. Scholtz HE, Pretorius SG, Wessels DH, et al. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the pharmacodynamics or pharmacokinetics of warfarin in healthy adult males [Abstract 09.30]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26-28, 2000, Seville, Spain
50. Kolilekas L, Anagnostopoulos GK, Lampaditis I. Potential interaction between telithromycin and warfarin. Ann Pharmacother 2004;38:1424-7
51. Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy 2004;24:945-9
52. O'Reilly RA. Stereoselective interactions of trimethoprim- sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5
53. Horn JR. Drug interactions with antibacterial agents. J Fam Pract 1995;41:81-90
54. Scholtz HE, Sultan E, Wessels D, et al. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [Abstract 09.29]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26-28, 2000, Seville, Spain